Dat'Aids Prevention
HIV Prevention in France : "Dat'AIDS Prevention"
1 other identifier
observational
6,500
3 countries
31
Brief Summary
DatAIDS prevention is a cohort study of HIV prevention in over 23 HIV sites in France including overseas, aiming to describe HIV prevention in every aspect including HIV screening, STI and hepatitis screening, post-exposure prophylaxis and pre-exposure prophylaxis
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jan 2019
Longer than P75 for all trials
31 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
December 21, 2018
CompletedStudy Start
First participant enrolled
January 1, 2019
CompletedFirst Posted
Study publicly available on registry
January 7, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2030
ExpectedStudy Completion
Last participant's last visit for all outcomes
January 1, 2030
January 15, 2026
January 1, 2026
11 years
December 21, 2018
January 14, 2026
Conditions
Outcome Measures
Primary Outcomes (1)
Number of patients enrolled for HIV prevention in the cohort
Demographics, risk factors clinical and biological characteristics, treatment of patients enrolled for HIV prevention in the cohort
From date of enrollment, through study completion, an average of 1 year
Secondary Outcomes (7)
Proportion of persons enrolled for pre-exposure prophylaxis in the cohort
From date of enrollment, through study completion, an average of 1 year
Proportion of persons enrolled for post-exposure prophylaxis in the cohort
From date of enrollment, through study completion, an average of 1 year
Proportion of persons enrolled for hepatitis screening in the cohort
From date of enrollment, through study completion, an average of 1 year
Proportion of persons enrolled for pre-exposure prophylaxis in the cohort according to national French guidelines
From date of enrollment, through study completion, an average of 1 year
Proportion of persons enrolled for post-exposure prophylaxis in the cohort according to national French guidelines
From date of enrollment, through study completion, an average of 1 year
- +2 more secondary outcomes
Eligibility Criteria
All persons attending for HIV prevention and seeking care at 23 centers using NADIS are included in the Dataids Prevention cohort after receiving oral information and giving written consent. NADIS is an electronic medical record (EMR) for HIV infection (and Hepatitis B virus (HBV), Hepatitis C virus (HCV), STI) and HIV prevention in French public hospitals. The Dataids Prevention study recruits persons HIV- and above the age of 18 years.
You may qualify if:
- Male and female over 18 years old,
- HIV negative
- Attending for :
- HIV screening
- Hepatitis screening
- STI screening / treatment
- Blood, body fluid or sexual exposure
- Post-exposure prophylaxis
- Pre-exposure prophylaxis
- Signed consent
You may not qualify if:
- HIV-infection
- Refusal to participate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- DatAidslead
Study Sites (31)
Hôpital Nord Franche Comté
Belfort, France
CHU Besançon - Hôpital Jean Minjoz
Besançon, France
CHRU Brest
Brest, France
CHU Clermont-Ferrand - Hôpital Gabriel-Montpied
Clermont-Ferrand, France
CHD Vendée
La Roche-sur-Yon, France
Hôpital Bicêtre - Assistance Publique des Hôpitaux de Paris
Le Kremlin-Bicêtre, France
CHU Limoges
Limoges, France
Hôpital de la Croix-Rousse - Hospices Civils de Lyon
Lyon, France
Hôpital Sainte Marguerite - Assistance Publique des Hôpitaux de Marseille
Marseille, France
IHU - Assistance Publique des Hôpitaux de Marseille
Marseille, France
CHR Metz-Thionville
Metz, France
Hôpital Gui de Chauliac
Montpellier, France
CHU Nancy - Hôpital Brabois
Nancy, France
CHU Nantes - Hôtel-Dieu
Nantes, France
CHU Nice - Hôpital l'Archet
Nice, France
CH Nîmes
Nîmes, France
CHR Orléans
Orléans, France
Groupe Hospitalier Pitié Salpêtrière - Assistance Publique des Hôpitaux de Paris
Paris, France
Hôpital Bichat - Assistance Publique des Hôpitaux de Paris
Paris, France
Hôpital Necker-Pasteur - Assistance Publique des Hôpitaux de Paris
Paris, France
Centre Hospitalier de Cornouaille
Quimper, France
CHU Reims - Hôpital Robert Debré
Reims, France
CHU Rennes - Hôpital Pontchaillou
Rennes, France
CHU Rouen
Rouen, France
CHU St Etienne - Hôpital Nord
Saint-Etienne, France
CHU Strasbourg - Hôpital Civil
Strasbourg, France
CHU Toulouse - Hôpital Purpan
Toulouse, France
CHU Tourcoing - Hôpital Guy Chatiliez
Tourcoing, France
CH Bretagne-Atlantique
Vannes, France
CHU de Guadeloupe
Pointe-à-Pitre, Guadeloupe
CHU de Martinique
Fort-de-France, Martinique
Study Officials
- PRINCIPAL INVESTIGATOR
Pascal PUGLIESE, MD
Centre Hospitalier Universitaire de Nice
- PRINCIPAL INVESTIGATOR
André CABIE, MD-PhD
Centre Hospitalier Universitaire de Martinique
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
December 21, 2018
First Posted
January 7, 2019
Study Start
January 1, 2019
Primary Completion (Estimated)
January 1, 2030
Study Completion (Estimated)
January 1, 2030
Last Updated
January 15, 2026
Record last verified: 2026-01
Data Sharing
- IPD Sharing
- Will not share